Literature DB >> 7116642

Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

A Grenier, A Lescault, C Laberge, R Gagné, O Mamer.   

Abstract

A technique designed to measure quantitatively succinylacetone (4,6-dioxoheptanoic acid) is presented. It essentially involves the inhibition of delta-aminolevulinate dehydratase (EC 4.2.1.24) by succinylacetone. Prior to their use in the assay, the samples are heated at 100 degrees C for 30 min in order to transform all succinylacetoacetate (3,5-dioxooctanedioic acid) to succinylacetone. By this transformation of the first abnormal metabolite specific to hereditary tyrosinemia to the second and last one, which is a powerful inhibitor of delta-aminolevulinate dehydratase, we determine in one sensitive assay the total amount of both. Succinylacetone was measured in sera and urines from 19 patients with hereditary tyrosinemia. All sera and urines contained succinylacetone at concentrations ranging, respectively, from 2 to 100 mumol/l and from 190 to 6000 mumol/g creatinine. The technique was also adapted to dried blood spots on paper and was used as a test complementary to blood tyrosine determination in mass screening for hereditary tyrosinemia. A total of 2412 samples having concentrations of 60 mg/l or more of tyrosine were assayed, and ten showed the presence of succinylacetone. These were all from newborns with hereditary tyrosinemia. The test has proven to virtually eliminate false positives, and, thereby, much clerical work and parental anxiety.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116642     DOI: 10.1016/0009-8981(82)90117-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  21 in total

1.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  Screening for tyrosinaemia type I.

Authors:  A C Hutchesson; S K Hall; M A Preece; A Green
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-05       Impact factor: 5.747

3.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.

Authors:  J L Aponte; G A Sega; L J Hauser; M S Dhar; C M Withrow; D A Carpenter; E M Rinchik; C T Culiat; D K Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

4.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I.

Authors:  S Z Kim; K G Kupke; L Ierardi-Curto; E Holme; J Greter; R M Tanguay; J Poudrier; M D'Astous; F Lettre; S H Hahn; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

6.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

7.  Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases.

Authors:  Cindy E L Lim; Klaus I Matthaei; Anneke C Blackburn; Richard P Davis; Jane E Dahlstrom; Mark E Koina; M W Anders; Philip G Board
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

8.  Clinical features and diagnostic approach in type I tyrosinaemia in an infant with cytomegaly virus infection and bacterial sepsis.

Authors:  M Wabitsch; F Pohlandt; D Leupold; R Berger; E Mönch; E Heinze; W Teller
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

9.  Tyrosinemia type I--diagnostic issues and prenatal diagnosis.

Authors:  Sunita Bijarnia; Ratna D Puri; Jean Ruel; George F Gray; Linda Jenkinson; Ishwar C Verma
Journal:  Indian J Pediatr       Date:  2006-02       Impact factor: 1.967

10.  Renal failure in adult patients with hereditary tyrosinaemia type I.

Authors:  E A Kvittingen; T Talseth; S Halvorsen; C Jakobs; T Hovig; A Flatmark
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.